Globe Biotech signs deal with ICDDR,B for COVID-19 vaccine trial

Staff Correspondent | Published: 17:13, Oct 14,2020 | Updated: 01:42, Oct 15,2020


Local drug firm Globe Biotech on Wednesday reached an agreement with the ICDDR,B for conducting human trial of its COVID-19 vaccine.

ICDDR,B, however, would require permission from the Bangladesh Medical Research Council before conducting the trial, officials said.

‘We’ve reached an agreement with our contract research organisation – ICDDR,B for conducting the phase-1 human trial,’ Globe Biotech in-charge of research and development Asif Mahmud told New Age.

On July 2, Globe Biotech announced that it was developing a COVID-19 vaccine after completing preliminary animal trials successfully.

On October 5, the company said that it had received ‘very promising’ results from pre-clinical trials on rabbits and mice.

Asif said that they were expecting they would get the approval from BMRCH soon to conduct the trial.

The protocol for the trial is yet to be developed, he said, adding, the protocol would be developed by the ICDDR,B and submit to the BMRC for the permission.

Want stories like this in your inbox?

Sign up to exclusive daily email